Expression of cyclin E and cyclin-dependent kinase inhibitor, p27KIP1 in uterine endometrial carcinoma:: Relationship with p53 status

被引:9
作者
Ahn, HJ
Kwon, KW
Choi, YJ
Cho, NH
机构
[1] Yonsei Univ, Coll Med, Seoul, South Korea
[2] Pochon CHA Univ, Coll Med, Dept Pathol, Seoul, South Korea
关键词
cyclin E; p27; p53; endometrial carcinoma;
D O I
10.1177/106689699800600404
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In an effort to clarify the cell-cycle regulator factors that affect the development and growth of endometrial carcinoma, immunohistochemical analyses of cyclin E, p27(KIP1), and p53 were performed in 36 cases of endometrial carcinoma (31 endometrioid and five serous carcinomas) and 40 cases of endometrial hyperplasia (20 simple hyperplasia and 20 complex hyperplasia). A correlation of expressions of these regulators with clinicopathologic features was analyzed. Overexpression of cyclin E was found in 0%, 30%, and 52.8% of simple hyperplasia, complex hyperplasia, and endometrial carcinoma, respectively. The p53 was overexpressed in 20%, 25%, and 69.4% of simple hyperplasia, complex hyperplasia, and endometrial carcinoma, respectively. Immunoreactivity of p53 in endometrial carcinoma was significantly higher than in simple and complex hyperplasia (p<.05). The immunoreactive indices of cyclin E and p53 in cases of stage Ic were higher than in cases of stage 1b (p=.047, .021, respectively). Immunoreactivity of p27 in endometrial carcinoma was significantly lower than in normal and hyperplastic endometrium (p<.05). There was a significant correlation between expressions of cyclin E and p53 and an inverse correlation between expressions of p27 and p53 (p<.001). These results suggest that the overexpression of cyclin E and p53 and the downregulation of p27 are implicated in the development and early progression of endometrial carcinoma. The results also suggest that regulatory factors have a close relationship with each other in endometrial hyperplasia and carcinoma.
引用
收藏
页码:205 / 212
页数:8
相关论文
共 29 条
[1]   FREQUENT AMPLIFICATION OF THE CYCLIN-E GENE IN HUMAN GASTRIC CARCINOMAS [J].
AKAMA, Y ;
YASUI, W ;
YOKOZAKI, H ;
KUNIYASU, H ;
KITAHARA, K ;
ISHIKAWA, T ;
TAHARA, E .
JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (07) :617-621
[2]  
AMBROS RA, 1994, CANCER, V73, P1686, DOI 10.1002/1097-0142(19940315)73:6<1686::AID-CNCR2820730622>3.0.CO
[3]  
2-W
[4]  
BUCKLEY MF, 1993, ONCOGENE, V8, P2127
[5]   ASSOCIATION OF HUMAN CYCLIN-E WITH A PERIODIC G(1)-S PHASE PROTEIN-KINASE [J].
DULIC, V ;
LEES, E ;
REED, SI .
SCIENCE, 1992, 257 (5078) :1958-1961
[6]   CYCLINS AS MARKERS OF TUMOR PROLIFERATION - IMMUNOCYTOCHEMICAL STUDIES IN BREAST-CANCER [J].
DUTTA, A ;
CHANDRA, R ;
LEITER, LM ;
LESTER, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) :5386-5390
[7]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[8]   RULES TO REPLICATE BY [J].
HEICHMAN, KA ;
ROBERTS, JM .
CELL, 1994, 79 (04) :557-562
[9]   CYCLINS AND CANCER .2. CYCLIN-D AND CDK INHIBITORS COME OF AGE [J].
HUNTER, T ;
PINES, J .
CELL, 1994, 79 (04) :573-582
[10]  
ITO K, 1994, CANCER RES, V54, P4667